ASH 2024: Polycythemia Vera and Myelofibrosis: Current and Future Standards of Care - Episode 15
Navigating Therapy Challenges in Myelofibrosis: Anemia Management and Disease-Specific Approaches
Panelists discuss studies aimed at combating dose-dependent anemia as a consequence of Janus kinase inhibitors (JAKi) treatment and share their thoughts on potential strategies to address this challenge.
Video content above is prompted by the following:
Dr Kuykendall to faculty: Dose-dependent anemia can be a consequence of treatment with JAKi. What are your thoughts on studies aimed at combating this challenge?
Related Content:
